業內人士:醫藥研發企業收購實驗猴為保障日常項目的開展和執行,自用為主,非囤積居奇
格隆匯6月10日丨昭衍新藥4月份發佈收購公吿稱,以合計約18億元收購廣西瑋美生物和雲南英茂生物100%股權。日前有媒體稱,國內醫藥行業出現猴荒,醫藥研發企業昭衍新藥正在大舉收購實驗猴。據業內人士稱,昭衍新藥收購兩家實驗模型公司主要是為了保障自己日常項目的開展和執行,以自用為主,屬於集團整體產業鏈的拓展,更好地助推客户的醫藥研發需求,非囤積居奇,請理性看待。昭衍新藥此前的公吿稱:收購有利於公司提升主營業務的服務能力:實驗模型是藥物非臨牀評價的主要實驗系統,是公司業務收入的主要載體;實驗模型供應和質量是非臨牀評價業務的基本保證、也經常是制約條件。本次股權收購有利於公司增強對關鍵性實驗模型的戰略儲備和成本控制,降低供應端風險,更好的滿足公司主營業務規模擴張需求,保障和提升公司非臨牀CRO的持續服務能力。收購有利於公司增強業務協同性,進一步將公司業務做大做強:公司在立足核心的非臨牀CRO服務的基礎上,通過橫向延伸和自建,產業鏈條已經覆蓋上游實驗模型業務。英茂生物從事業務屬於本公司主營業務上游產業,本次收購股權是公司業務進一步向上游拓展的重要舉措,符合公司的整體戰略,有利於提高公司可持續發展及抗風險能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.